Investor Update
Logotype for Ingredion Incorporated

Ingredion (INGR) Investor Update summary

Event summary combining transcript, slides, and related documents.

Logotype for Ingredion Incorporated

Investor Update summary

14 Jan, 2026

Strategic Vision, Market Opportunity, and Consumer Trends

  • The texture and healthful solutions market is estimated at $20 billion, with strong growth potential in emerging markets and packaged food retail valued at $600 billion.

  • Focus on becoming the leading provider for texture and healthful solutions, leveraging advanced ingredient technology, consumer insights, and a global footprint of 22 plants and local teams.

  • Clean label and affordability are major trends, with 75% of consumers attracted to 'all natural' claims and 80% attentive to food prices.

  • Urbanization, economic growth, convenience, and multicultural food trends are increasing demand for diverse textures and delivery-friendly products.

  • Texture is a key factor in consumer satisfaction, influencing repeat purchases and overall product acceptance, with 40% of overall liking attributed to texture and over 50% of consumers rejecting products with undesirable texture.

Capabilities, Innovation, and Differentiation

  • Proprietary plant science and a broad portfolio of over 3,500 specialty starches, hydrocolloids, fibers, and sweeteners enable unique ingredient functionality and customized solutions.

  • Investments in data science, AI, and R&D (~2.5% of sales) support predictive formulation, rapid prototyping, and improved product launch success rates.

  • Sensory science, Culinology, and analytical science are integrated to translate consumer preferences into winning product designs.

  • Consultative and co-creation services are monetized, offering flexibility in ingredients, solutions, or advisory services.

  • Strategic M&A and organic investments, including $160M in starch-based texturizers and acquisitions like TIC Gums and KaTech, expand capabilities and fill gaps in biotech and synthetic biology.

Financial Outlook and Performance

  • The segment targets 5%-6% net sales CAGR and 8%-10% operating income CAGR from 2025–2028, aiming for ~$3B net sales and $450–$550M operating income by 2028.

  • Gross margin is targeted to expand from 27%-28% to above 30%, with EBITDA margin aiming to reach 20% by 2028.

  • Margin growth is expected from higher value product mix, premium pricing, and enhanced solutions and services.

  • Recent quarter saw 11% volume growth in the segment, with momentum expected to continue, especially in Asia-Pacific and emerging markets.

  • SG&A is expected at 12–14% of sales, supporting growth and technical capabilities.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more